Last edition
News about "Kenneth Custer"
US FDA Approves Lilly's Onswik for Adults Living with T2D
The US FDA has approved Lilly’s Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin injection for adults with Type 2 Diabetes (T2D).
Kenneth Custer | 25/09/2026 | By News Bureau
Lilly's Triple Agonist, Retatrutide, Successful in 2 Additional Phase 3 Obesity Trials
Lilly's Triple Agonist, Retatrutide, Successful in 2 Additional Phase 3 Obesity Trials. The company plans to submit a Biologics License Application (BLA) for retatrutide to the US Food and Drug Administration (FDA) in Q1 2027.
Kenneth Custer | 25/07/2026 | By News Bureau | 135
Lilly's Retatrutide Shows Strong A1C, Weight Reduction in Phase-III Diabetes Trial
Eli Lilly’s Retatrutide reduced A1C by up to two percent and delivered average weight loss of 36.6 lbs in its phase-III TRANSCEND-T2D-1 trial, with continued weight reduction observed through 40 weeks in type-II diabetes mellitus patients.
Kenneth Custer | 20/03/2026 | By News Bureau | 200
Orforglipron by Lily Shows Significant Weight Loss and Cardiometabolic Gains in ATTAIN-1 Results
Orforglipron by Eli Lily demonstrated significant improvements across key cardiometabolic risk factors, supporting its potential as a treatment option for millions living with obesity.
Kenneth Custer | 18/09/2025 | By Dineshwori | 591
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy